Can CBD Help With Genital Pain In Women? Curaleaf To Present Positive Results From Studies

Curaleaf International part of Curaleaf Holdings CURLFCURA, announced that chief scientific officer, Dr Barbara Pacchetti will present research on one clinical study and three preclinical studies at a conference on medical cannabis on 21-22 October 2022. These papers have been peer-reviewed and selected for presentation and publication in the official Conference Proceedings Journal Medical Cannabis and Cannabinoids.

Research to be presented from the clinical study focuses on the delivery of a CBD preparation to patients with Vestibulodynia which is a prevalent form of chronic genital pain in women with no standard treatment. The study, a randomized placebo control study, of 60 patients showed significant improvement of outcomes on pain, genital pain before, during or after sex, pelvic muscular tone and neurometer parameters, which highlights implications for its anti-inflammatory, anti-nociceptive action and anti-neuropathic therapeutic potential. The title of the paper is: Transmucosal delivery of cannabidiol using vestibular electroporation in patients with vestibulodynia: interim analysis of a randomized, blinded prospective trial. The co-authors are F. Murina, Prof. MD., F. Vicariotto, Prof. MD and Pacchetti.

Preclinical research to be presented focuses on the potential positive impact of CBD on the treatment of several psychiatric disorders and inflammatory disease, the therapeutic potential for migraine pain and trigeminal excitability related to migraine.

Dr. Barbara Pacchetti, chief scientific officer at Curaleaf International, stated, “We are very pleased with the findings from our clinical study on the delivery of CBD to treat patients with Vestibulodynia, and that it is showing a significant improvement in pain outcomes for patients. Additionally, the preclinical research on the therapeutic potential of CBD to treat a number of other indications is also encouraging and I look forward to presenting this to the scientific community and to furthering our research into the potential for CBD. We believe the growth and understanding of medical cannabis must be underpinned by the most robust science. Curaleaf International is working with some of the world’s leading academic institutions such as Imperial College, the University of Milan and University of Insubria and we look forward to further updating all stakeholders with our progress.”

Photo by Jeff W on Unsplash

Related News

Where To Buy Legal Weed These Days: Curaleaf, Cresco & Other Operators Launch Sales At New Locations

Do Any States Face The Risk Of A Dominant Cannabis Market Operator?

How Cannabis Can Redefine Corporate Wellness